Marina Biotech Terminates Negotiations for Sale of Its

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Marina Biotech Terminates Negotiations for Sale of Its Nucleic Acid Therapeutic Assets

BOTHELL, WA--(Marketwired - May 3, 2016) - Marina Biotech, Inc. ( OTCQB : MRNA ), a leading nucleic acid-based drug discovery and development company focused on rare diseases announced that they have terminated negotiations with Microlin Bio, Inc. for the sale of the Company's nucleic acid therapeutic assets as previously reported on March 15, 2016.

"After waiting six weeks for either a draft asset purchase agreement or a financing term sheet, we were finally presented a financing document yesterday to purchase our 'aged-debt,'" stated J. Michael French, president and chief executive officer at Marina Biotech. "The Marina Board of Directors and I found the lack of progress totally unacceptable and terminated any further discussions with Microlin. We believe we can better serve our shareholders by pursuing other alternatives at this time."

About Marina Biotech, Inc. Marina Biotech is an oligonucleotide therapeutics company with broad drug discovery technologies providing the ability to develop proprietary single and double-stranded nucleic acid therapeutics including siRNAs, microRNA mimics, antagomirs, and antisense compounds, including messengerRNA therapeutics. These technologies were built via a roll-up strategy to discover and develop different types of nucleic acid therapeutics in order to modulate (up or down) a specific protein(s) which is either being produced too much or too little thereby causing a particular disease. We believe that the Marina Biotech technologies have unique strengths as a drug discovery engine for the development of nucleic acid-based therapeutics for rare and orphan diseases. Further, we believe Marina Biotech is the only company in the sector that has a delivery technology in human clinical trials with differentiated classes of payloads, through licensees ProNAi Therapeutics and Mirna Therapeutics, delivering single-stranded and double-stranded nucleic acid payloads, respectively. Our novel chemistries and other delivery technologies have been validated through license agreements with Roche, Novartis, Monsanto, and Tekmira. The Marina Biotech pipeline currently includes a clinical program in Familial Adenomatous Polyposis (a precancerous syndrome) and a preclinical program in myotonic dystrophy. Marina Biotech's goal is to improve human health through the development of RNAi- and oligonucleotide-based compounds and drug delivery technologies that together provide superior therapeutic options for patients. Additional information about Marina Biotech is available at www.marinabio.com .

Marina Biotech Forward-Looking Statements Statements made in this news release may be forward-looking statements within the meaning of Federal Securities laws that are subject to certain risks and uncertainties and involve factors that may cause actual results to differ materially from those projected or suggested. Factors that could cause actual results to differ materially from those in forward-looking statements include, but are not limited to: (i) the ability of Marina Biotech to obtain additional funding; (ii) the ability of Marina Biotech to attract and/or maintain manufacturing, research, development and commercialization partners; (iii) the ability of Marina Biotech and/or a partner to successfully complete product research and development, including preclinical and clinical studies and commercialization; (iv) the ability of Marina Biotech and/or a partner to obtain required governmental approvals; and (v) the ability of Marina Biotech and/or a partner to develop and commercialize products prior to, and that can compete favorably with those of, competitors. Additional factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statements are contained in Marina Biotech's most recent filings with the Securities and Exchange Commission. Marina Biotech assumes no obligation to update or supplement forward-looking statements because of subsequent events.

For Marina inquires: J. Michael French President and CEO Marina Biotech, Inc. admin@marinabio.com (425) 892-4322

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Insight Into Midland TX Real Estate Sales Timing

Updated Category News Views 70

How Fast Do Homes Move in Midland? This ain't my first rodeo predicting the real estate rollercoaster in Texas. Midland's housing market is one nifty beast—homes can either sell like hotcakes or just sit gathering dust. You got HelloNation pulling in DeLaura Gammage, a pro who knows the terrain like the back of her hand, to spell out the why and how long it'll take to...

Continue Reading
Radnostix Sees Mixed Results, Plans Strategic Shift

Updated Category News Views 90

Radnostix: A Rocky Third Quarter with Glimmers of Hope Alright, sit back and digest this: Radnostix, the company once known as International Isotopes Inc., is currently in the midst of a renovation of sorts. They just reported their financial results for the third quarter of 2026, and honestly, they're a mixed bag. Revenue Falls but Theranostics Shines Quarterly revenue...

Continue Reading
PEGATRON Unveils AI and HPC Advances at SC26

Updated Category News Views 96

Revamping AI with High-Density Computing You know, back in the day, AI was just about training models and running basic inference. But now, it's all about these crazy agentic AI tasks—autonomous agents doing things I couldn't have imagined. PEGATRON's Evolution in Infrastructure PEGATRON's latest move at SC26 is a real leap forward in this ongoing AI saga. They're...

Continue Reading
Mall of America Strives for World Record This Black Friday

Updated Category News Views 228

History in the Making at Mall of America Yeah, it seems these folks are not just about shopping anymore. The Mall of America is aiming to set the bar high this Black Friday, eyeing a GUINNESS WORLD RECORDS title for the most people holding up the same shopping bag all at once. Imagine a thousand people, synchronized like a flash mob—only with shopping bags instead of...

Continue Reading
Lilly Endowment Boosts Military Families with $10M Grant

Updated Category News Views 70

A Game-Changer for Semper Fi & America's Fund Dive in, folks. What we've got here is a hefty chunk of change — $10 million to be precise — dropped into Semper Fi & America's Fund's lap by Lilly Endowment Inc. We're talking about a grant designed to shore up the long-term support system crafted for the brave souls in military families. It’s about time a significant...

Continue Reading
Silvi's Expansion Push: New Terminal in Wilmington

Updated Category News Views 166

Silvi's Latest Bet on the Southeast You know, sometimes you get a gut feeling that a company is rolling out chess moves instead of checkers. That’s what Silvi Materials is up to with their new project in Wilmington. It’s not just some fancy cement terminal—it’s a calculated expansion into the heart of the Southeast construction market. The Port of Wilmington’s...

Continue Reading
PawnMate Boosts Inventory Efficiency for Pawnshops

Updated Category News Views 85

RFID Technology: Breathing New Life into Pawnshops Let's get things rolling with the cold, hard truth that pawnshops aren't exactly what most folks expect when it comes to cutting-edge technology. But times are a-changin', and PawnMate’s RFID Inventory Module is the latest twist in this industry storyline. It's like swapping out a rusty toolbox for a brand-new set of...

Continue Reading
Lululemon Faces Class Action: Navigating Investor Impact

Updated Category News Views 103

Lululemon's Legal Storm: Understanding the Background If you thought the yoga gear game was all about stretch and flexibility, Lululemon Athletica, Inc (NASDAQ: LULU) just yanked us back to reality. The company finds itself in a legal tangle with its shareholders following a dismal performance report and a subsequent lawsuit. This situation has unfolded like a second-rate...

Continue Reading
Saint Luis Rey Launches Exclusive Palatinos Vitola

Updated Category News Views 110

New Beginnings for the Saint Luis Rey Brand You think you've seen it all in the cigar world, but then comes a debut like this that lights a fire under the lush tradition of Cuba. Enter Saint Luis Rey's new Palatinos vitola, a blend wrapped in the mystique of exclusivity for La Casa del Habano and Habanos Specialists. Whether you're a seasoned connoisseur or just dipping...

Continue Reading
Texxon Faces Revenue Slide Amid Strategic Shifts

Updated Category News Views 83

Texxon's Strategic Transitions and Financial Headaches Texxon Holding Limited (NASDAQ:NPT) just laid their cards on the table, unveiling a mixed bag in their fiscal year 2026 results. As the world's chemical and plastics scene faces winds of change, Texxon buckled down and tried to steer the ship clear from the rocks. It's a balancing act juggling market headwinds, a new...

Continue Reading

Top 5 Most Recently Viewed Articles

Insights into abrdn Japan Equity Fund's Tender Offer Strategy

Updated Category News Views 303

Understanding the Tender Offer and Reorganization Process abrdn Japan Equity Fund, Inc. (NYSE: JEQ) is entering an exciting phase as it moves forward with additional details regarding its tender offer and the anticipated reorganization with abrdn Global Infrastructure Income Fund (NYSE: ASGI). As this process unfolds, it is essential for investors to grasp the key details...

Continue Reading
TriNet Welcomes Sidney Majalya as New Chief Legal Officer

Updated Category News Views 158

TriNet Welcomes New Chief Legal Officer TriNet, a prominent provider of comprehensive human resources solutions tailored for small and medium-sized businesses, has recently undergone notable leadership changes. The company is excited to announce the appointment of Sidney Majalya as its new Chief Legal Officer and Secretary, marking an important milestone in its evolution....

Continue Reading
Exploring the Future Growth of the SDx Market by 2034

Updated Category News Views 94

Understanding the Growth of the Software-Defined Anything Market The global Software-Defined Anything (SDx) market is experiencing a remarkable transformation. Recently, it was reported that the market is set to grow from USD 44.46 billion in 2024 to an estimated USD 383.65 billion by 2034, achieving a compound annual growth rate (CAGR) of 24.0%. This expansion signals a...

Continue Reading
Safe Harbor Financial Strengthens Position After Successful Capital Raise

Updated Category News Views 245

Safe Harbor Financial's Significant Achievements Recently, Safe Harbor Financial, known as SHF Holdings, Inc. (NASDAQ: SHFS), celebrated a considerable milestone. They regained compliance with Nasdaq's listing requirements, proving their resiliency in the dynamic financial services sector aimed at the cannabis industry. This success was paired with a noteworthy capital...

Continue Reading
UNITE's Dignity Index: Insights from the Vance-Walz Debate

Updated Category News Views 125

UNITE Unveils Dignity Index Results Post-Debate UNITE, a non-profit organization aimed at reducing political divisions, recently showcased its Dignity Index scores following the Vice-Presidential debate between Senator J.D. Vance and Governor Tim Walz. This initiative was co-founded by Tim Shriver, who emphasizes the importance of dignity in political discourse. The...

Continue Reading